dpp 4 and glp 1 GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? dpp-4_inhibitors [TUSOM | Pharmwiki]

Peminda Cabandugama, MD, an endocrinologist and obesity medicine specialist at Cleveland Clinic in Ohio, found the results to be slightly surprising. The pharmacokinetics [how drugs move through the body] of GLP-1 medications show a half-life of 5 days, which means the current standard of using these medications every 7 days is also stretching this out, says Dr

Seeing how they showed up for the GLP-1 community

doi: 10.1038/s41598-017-09898-4 [DOI] [PMC free article] [PubMed] [Google Scholar] 27

Multiple large-scale observational studies and peer-reviewed analyses published in 2025 and 2026 have contributed substantially to this field

Importantly, a substantial number of patients had multiple reasons noted for stopping (21%), underscoring the complexity of real-world medication use and the challenges patients face when using these therapies